Abstract 21151: Safety and Feasibility Report of Investigational Therapy With Interleukin-11 Against Acute Myocardial Infarction

Introduction: The benefits of vessel recanalization in acute myocardial infarction (AMI) are limited by ischemia/reperfusion (IR) injury. We have reported IL-11, a kind of IL-6 family cytokine, confers resistance to IR injury on cardiomyocytes both in vitro and in vivo and reduces infarct size and improved ventricular function after I/R injury in vivo. Importantly, recombinant human IL-11 (rhIL-11) was clinically used for the prevention of severe thrombocytopenia after chemotherapy under the approval of FDA. Hypothesis: The aim of this study was to evaluate the safety and feasibility of rhIL-11, adjunct to primary percutaneous coronary intervention (PCI) in AMI. Methods: Four patients with STEMI undergoing primary PCI were enrolled based on inclusion criteria, such as culprit lesion of #6 or #7 with TIMI flow grade 0 or 1 on coronary angiography (CAG). Just after diagnosis by CAG, rhIL-11 (6 or 25 μg/kg) was intravenously administered for a period of 3 hours (hr). The primary endpoint were safety and tole...